First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy
23 janv. 2023 07h01 HE
|
Consilium Strategic Communications
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy Phase I/II trial will assess safety and efficacy of SMART101 in accelerating immune reconstitution to...
Global Hemato Oncology Testing Market Report 2022 to 2027: Drug Diagnostics Co-Development Presents Opportunities
12 déc. 2022 08h14 HE
|
Research and Markets
Dublin, Dec. 12, 2022 (GLOBE NEWSWIRE) -- The "Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma...
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
11 déc. 2022 09h00 HE
|
Aptose Biosciences, Inc.
Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to...
ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
15 nov. 2022 08h32 HE
|
ExCellThera
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its...
Global Leukapheresis Market Report 2022: Increased Demand for Leukopaks in Clinical Research Driving Growth
25 oct. 2022 06h28 HE
|
Research and Markets
Dublin, Oct. 25, 2022 (GLOBE NEWSWIRE) -- The "Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma),...
T-Cell Therapy Market Size to Hit $21+ Billion with Booming CAGR Value of 20.7% by 2028 | The Insight Partners
20 oct. 2022 09h22 HE
|
The Insight Partners
New York, Oct. 20, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "T-cell Therapy Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19 Impact and...
Oncolyze, a Company Aiming to Treat Cancer by Exploding Cancer Cells, is Now Accepting Investments. Own a Piece in the Future of Cancer Treatment.
23 août 2022 12h00 HE
|
Oncolyze Inc
NEW YORK, Aug. 23, 2022 (GLOBE NEWSWIRE) -- After successfully completing in vitro and in vivo (mice) experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer...
Doxorubicin Market Revenue to Cross $1,983.40 million by 2028 to Rise at a Stellar CAGR of 6.1% by 2028 | Exclusive Research by The Insight Partners
12 juil. 2022 10h54 HE
|
The Insight Partners
New York, July 12, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Doxorubicin Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Drug Formulation,...
UFCW Canada lifetime fundraising for Leukemia & Lymphoma Society of Canada tops $49 million thanks to $1.86 million campaign in 2021-2022
17 juin 2022 13h22 HE
|
UFCW Canada
TORONTO, June 17, 2022 (GLOBE NEWSWIRE) -- Another year of pandemic restrictions presented unique challenges for UFCW Canada’s fundraising efforts on behalf of the Leukemia & Lymphoma Society...
Protein Kinase Inhibitors in Oncology Analysis Service 2022: Must have Handbook for Any Business Developer, BI/CI Operative or Clinical Developer
15 juin 2022 07h58 HE
|
Research and Markets
Dublin, June 15, 2022 (GLOBE NEWSWIRE) -- The "Protein Kinase Inhibitors in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.Protein Kinase Inhibitors in...